EPS for Cellular Biomedicine Group, Inc. (CBMG) Expected At $-0.54

October 14, 2018 - By Michael Collier

Cellular Biomedicine Group, Inc. (NASDAQ:CBMG) LogoInvestors sentiment increased to 3 in 2018 Q2. Its up 0.40, from 2.6 in 2018Q1. It improved, as 6 investors sold Cellular Biomedicine Group, Inc. shares while 2 reduced holdings. 15 funds opened positions while 9 raised stakes. 1.41 million shares or 105.26% more from 685,017 shares in 2018Q1 were reported.
588,852 were accumulated by Blackrock. Northern Tru holds 0% or 81,758 shares. Deutsche Natl Bank Ag reported 0% in Cellular Biomedicine Group, Inc. (NASDAQ:CBMG). Jpmorgan Chase And invested 0% in Cellular Biomedicine Group, Inc. (NASDAQ:CBMG). Bancorporation Of America De reported 1,852 shares. Geode Cap Mngmt Ltd Liability stated it has 92,023 shares. Rhumbline Advisers holds 0% or 10,650 shares. Piedmont Invest Advisors Ltd Liability Com invested 0% in Cellular Biomedicine Group, Inc. (NASDAQ:CBMG). Legal & General Gru Public Ltd stated it has 1,728 shares. Morgan Stanley, New York-based fund reported 26,088 shares. State Street Corp has 0% invested in Cellular Biomedicine Group, Inc. (NASDAQ:CBMG). California State Teachers Retirement Sys invested in 0% or 17,757 shares. Ameritas Inv Prtn Inc holds 0% or 958 shares in its portfolio. 34,579 were accumulated by Natl Bank Of Ny Mellon Corp. Schwab Charles Inv Mngmt stated it has 0% in Cellular Biomedicine Group, Inc. (NASDAQ:CBMG).

Analysts expect Cellular Biomedicine Group, Inc. (NASDAQ:CBMG) to report $-0.54 EPS on November, 8.They anticipate $0.11 EPS change or 25.58 % from last quarter’s $-0.43 EPS. After having $-0.53 EPS previously, Cellular Biomedicine Group, Inc.’s analysts see 1.89 % EPS growth. The stock decreased 0.38% or $0.06 during the last trading session, reaching $15.62. About 57,084 shares traded. Cellular Biomedicine Group, Inc. (NASDAQ:CBMG) has risen 83.78% since October 14, 2017 and is uptrending. It has outperformed by 68.16% the S&P500.

Cellular Biomedicine Group, Inc. (NASDAQ:CBMG) Ratings Coverage

Among 2 analysts covering Cellular Biomedicine Gr (NASDAQ:CBMG), 1 have Buy rating, 0 Sell and 1 Hold. Therefore 50% are positive. Cellular Biomedicine Gr had 2 analyst reports since June 15, 2018 according to SRatingsIntel. The stock of Cellular Biomedicine Group, Inc. (NASDAQ:CBMG) earned “Buy” rating by FBR Capital on Wednesday, October 3.

Cellular Biomedicine Group Inc., a biopharmaceutical company, develops treatments for cancerous and degenerative diseases in Greater China. The company has market cap of $280.72 million. It focuses on developing and marketing cell therapies to treat serious diseases, such as cancer, orthopedic, and various inflammatory diseases, as well as metabolic diseases. It currently has negative earnings. The firm develops treatments utilizing proprietary cell based technologies, including immune cell therapy for the treatment of a range of cancers; human adipose-derived mesenchymal progenitor cells for the treatment of joint and autoimmune diseases; and tumor cell specific dendritic cell therapy.

More important recent Cellular Biomedicine Group, Inc. (NASDAQ:CBMG) news were published by: Benzinga.com which released: “44 Biggest Movers From Yesterday” on October 12, 2018, also Seekingalpha.com published article titled: “Cellular Biomedicine inks deal with Novartis for CAR-T cell therapy for patients in China”, Seekingalpha.com published: “Cellular Biomedicine obtained NCI patent license for neoantigen-reactive TIL technology to treat solid tumors” on October 03, 2018. More interesting news about Cellular Biomedicine Group, Inc. (NASDAQ:CBMG) was released by: Globenewswire.com and their article: “Cellular Biomedicine Group Obtained NCI Patent License for Next Generation Neoantigen-Reactive Tumor Infiltrating …” with publication date: October 03, 2018.

Cellular Biomedicine Group, Inc. (NASDAQ:CBMG) Institutional Positions Chart

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

>